PLCG2 and B-cell chronic lymphocytic leukemia: CLL patients may develop resistance against BTKi by different mechanisms, including mutations of the BTK binding site and of the gene encoding phospholipase C Gamma 2 (PLCG2), which acts downstream of BTK in the BCR signaling cascade.